Login
$AXSM
$137.01 -$4.68 (3.3%) Live

$AXSM 8-K/A SEC Filings

Filed On Filing
21 Jul 2022 8-K/A: Financial Statements and Exhibits

On March 25, 2022, Axsome Therapeutics, Inc. (the “Company" or "acquirer”) entered into an Asset Purchase Agreement (the “Purchase Agreement”) with Jazz Pharmaceuticals plc, pursuant to which the Company will acquire Sunosi (the “Product...

31 Mar 2022 8-K/A: Entry into a Material Definitive Agreement

CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. [***] INDICATES THAT INFORMATION HAS BEEN REDACTED.

22 Sep 2020 8-K/A: Other Events

Axsome Therapeutics Announces Expedited Development of AXS-12 for the Treatment of Narcolepsy Based on FDA Breakthrough Therapy Meeting

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support